首页 | 本学科首页   官方微博 | 高级检索  
     


Survival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatment
Authors:Phu Quoc Lê MD  Béatrice Gulbis MD  PhD  Laurence Dedeken MD  Sophie Dupont MD  Anna Vanderfaeillie MD  Catherine Heijmans MD  Sophie Huybrechts MD  Christine Devalck MD  André Efira MD  Marie‐Françoise Dresse MD  PhD  Laurence Rozen  Fleur Samantha Benghiat MD  PhD  Alina Ferster MD
Affiliation:1. Hemato‐Oncology Unit, H?pital Universitaire des Enfants Reine Fabiola, U.L.B., Brussels, Belgium;2. Department of Clinical Chemistry, H?pital Erasme, U.L.B., Brussels, Belgium;3. Hemato‐Oncology Unit, Cliniques Universitaires Saint Luc, Brussels, Belgium;4. Department of Pediatrics, H?pital Saint‐Pierre, U.L.B., Brussels, Belgium;5. Department of Pediatrics, H?pital de Jolimont, La Louvière, Belgium;6. Hemato‐Oncology Unit, H?pital Universitaire Brugmann, U.L.B., Brussels, Belgium;7. Hemato‐Oncology Unit, H?pital Régional de la Citadelle, ULg, Liège, Belgium;8. Laboratory of Hematology, CHU‐Brugmann, H?pital Universitaire des Enfants Reine Fabiola, U.L.B., Brussels, Belgium;9. Hemato‐Oncology Unit, H?pital Erasme, U.L.B., Brussels, Belgium
Abstract:
Keywords:hydroxyurea  mortality  sickle cell disease  survival
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号